EA
AKBA icon

Emerald Acquisition’s Akebia Therapeutics AKBA Stock Holding History

Emerald Acquisition’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-38,666
Closed -$289K – 2981
2016
Q2 		$289K Buy
+38,666
New +$338K ﹤0.01% 2643

Other funds holding AKBA

EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Emerald Acquisition's AKBA Position: Q3 2016 in Review

Emerald Acquisition sold out of Akebia Therapeutics (AKBA) in Q3 2016, closing a stake of 38,666 shares — an estimated $289K sold.

Emerald Acquisition first reported a position in AKBA in Q2 2016 and held it in 1 quarter. The position peaked at $289K in Q2 2016. 86 funds tracked by Wall St. Rank hold AKBA as of Q3 2016.

  • Emerald Acquisition reported no remaining Akebia Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Emerald Acquisition sold 38,666 Akebia Therapeutics shares in Q3 2016, an estimated $289K.
  • Emerald Acquisition first reported a position in Akebia Therapeutics in Q2 2016 and held it in 1 quarter.
  • Emerald Acquisition's Akebia Therapeutics position peaked at $289K in Q2 2016.
  • 86 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.